NEW YORK, Sept. 11, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is reminding investors that class action lawsuits may be filed on behalf of shareholders of Co-Diagnostics, Inc. (NASDAQ : CODX) , Ampio Pharmaceuticals, Inc. (NYSEAmerican: AMPE), Sinovac Biotech Ltd. (NASDAQ: SVA) and Lottery.com, Inc. (NASDAQ: LTRY, LTRYW). Shareholders have until the deadlines below to petition the court to appear as lead plaintiffs. For more information on each case, see the link provided.

Co-Diagnostics, Inc. (NASDAQ:CODX)

Class Period: May 12, 2022 – August 11, 2022

Lead Plaintiff Deadline: October 17, 2022

On August 11, 2022, Co-Dx shocked investors when the company issued a press release and filed a report with the Securities and Exchange Commission, disclosing its financial results for the quarter ended June 30, 2022. The company reported revenue of $5.0 million for the quarter ended June 30, 2022, compared to $27.4 million for the same period last year, a decrease of nearly 82%. The company attributed the decline primarily to lower demand for the Logix Smart™ COVID-19 test.

As a result of this news, the price of Co-Dx common stock fell $1.98 per share, or 30.65%, to close at $4.48 per share on August 12, 2022.

The lawsuit alleges that the defendants made false and/or misleading statements and/or failed to disclose the following: (1) Co-Diagnostics experienced a significant drop in demand for Logix Smart^TM COVID-19 test and demand for his Logix Smart^TM COVID-19 testing had declined sharply for the full quarter ended June 30, 2022; and (2) as a result, Defendant’s positive comments regarding demand for its Logix Smart^TM COVID-19 test lacked a sound basis. As the true details emerged, the lawsuit alleges that investors suffered damage.

For more information on the Co-Dx class action go to: https://bespc.com/cases/CODX

Ampio Pharmaceuticals, Inc. (NYSEAmerican: AMPE)

School lesson:…